Performance of a live multi-gateway LoRaWAN and interference measurement across indoor and outdoor localities

Little work has been reported on the magnitude and impact of interference with the performance of Internet of Things (IoT) applications operated by Long-Range Wide-Area Network (LoRaWAN) in the unlicensed 868 MHz Industrial, Scientific, and Medical (ISM) band. The propagation performance and signal activity measurement of such technologies can give many insights to effectively build long-range wireless communications in a Non-Line of Sight (NLOS) environment. In this paper, the performance of a live multi-gateway in indoor office site in Glasgow city was analysed in 26 days of traffic measurement. The indoor network performances were compared to similar performance measurements from outdoor LoRaWAN test traffic generated across Glasgow Central Business District (CBD) and elsewhere on the same LoRaWAN. The results revealed 99.95% packet transfer success on the first attempt in the indoor site compared to 95.7% at the external site. The analysis shows that interference is attributed to nearly 50 X greater LoRaWAN outdoor packet loss than indoor. The interference measurement results showed a 13.2–97.3% and 4.8–54% probability of interfering signals, respectively, in the mandatory Long-Range (LoRa) uplink and downlink channels, capable of limiting LoRa coverage in some areas

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Background Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety, reactogenicity, and immunogenicity of fourth-dose boosters against COVID-19.Methods The COV-BOOST trial is a multicentre, blinded, phase 2, randomised controlled trial of seven COVID-19 vaccines given as third-dose boosters at 18 sites in the UK. This sub-study enrolled participants who had received BNT162b2 (Pfizer-BioNTech) as their third dose in COV-BOOST and randomly assigned them (1:1) to receive a fourth dose of either BNT162b2 (30 µg in 0·30 mL; full dose) or mRNA-1273 (Moderna; 50 µg in 0·25 mL; half dose) via intramuscular injection into the upper arm. The computer-generated randomisation list was created by the study statisticians with random block sizes of two or four. Participants and all study staff not delivering the vaccines were masked to treatment allocation. The coprimary outcomes were safety and reactogenicity, and immunogenicity (antispike protein IgG titres by ELISA and cellular immune response by ELISpot). We compared immunogenicity at 28 days after the third dose versus 14 days after the fourth dose and at day 0 versus day 14 relative to the fourth dose. Safety and reactogenicity were assessed in the per-protocol population, which comprised all participants who received a fourth-dose booster regardless of their SARS-CoV-2 serostatus. Immunogenicity was primarily analysed in a modified intention-to-treat population comprising seronegative participants who had received a fourth-dose booster and had available endpoint data. This trial is registered with ISRCTN, 73765130, and is ongoing.Findings Between Jan 11 and Jan 25, 2022, 166 participants were screened, randomly assigned, and received either full-dose BNT162b2 (n=83) or half-dose mRNA-1273 (n=83) as a fourth dose. The median age of these participants was 70·1 years (IQR 51·6–77·5) and 86 (52%) of 166 participants were female and 80 (48%) were male. The median interval between the third and fourth doses was 208·5 days (IQR 203·3–214·8). Pain was the most common local solicited adverse event and fatigue was the most common systemic solicited adverse event after BNT162b2 or mRNA-1273 booster doses. None of three serious adverse events reported after a fourth dose with BNT162b2 were related to the study vaccine. In the BNT162b2 group, geometric mean anti-spike protein IgG concentration at day 28 after the third dose was 23 325 ELISA laboratory units (ELU)/mL (95% CI 20 030–27 162), which increased to 37 460 ELU/mL (31 996–43 857) at day 14 after the fourth dose, representing a significant fold change (geometric mean 1·59, 95% CI 1·41–1·78). There was a significant increase in geometric mean anti-spike protein IgG concentration from 28 days after the third dose (25 317 ELU/mL, 95% CI 20 996–30 528) to 14 days after a fourth dose of mRNA-1273 (54 936 ELU/mL, 46 826–64 452), with a geometric mean fold change of 2·19 (1·90–2·52). The fold changes in anti-spike protein IgG titres from before (day 0) to after (day 14) the fourth dose were 12·19 (95% CI 10·37–14·32) and 15·90 (12·92–19·58) in the BNT162b2 and mRNA-1273 groups, respectively. T-cell responses were also boosted after the fourth dose (eg, the fold changes for the wild-type variant from before to after the fourth dose were 7·32 [95% CI 3·24–16·54] in the BNT162b2 group and 6·22 [3·90–9·92] in the mRNA-1273 group).Interpretation Fourth-dose COVID-19 mRNA booster vaccines are well tolerated and boost cellular and humoral immunity. Peak responses after the fourth dose were similar to, and possibly better than, peak responses after the third dose

Title: Validation of trunk mounted inertial sensors for analysing running biomechanics. Find us at Queensland Sports Technology Cluster Introduction

Abstract: The biomechanical evaluation of elite athletes often requires the use of sophisticated laboratory based equipment that is restrictive, cumbersome, and often unsuitable for use in a training and competition environment. Small, light-weight unobtrusive centre-of-mass tri-axial accelerometers can be used to collect data but may not reveal all the information of interest. This validation of centre-of-mass tri-axial accelerometry uses previously reporte

Measurement of energy expenditure in elite athletes using MEMS-based triaxial accelerometers

Fitness development and performance assessment of elite athletes requires an understanding of many physiological factors, many of these are direct and indirect measures of athlete energy expenditure. Many methods are physiological factor assessments and require the athlete to be constrained by laboratory equipment or periodic interruption of activity to take measurements such as blood samples are required to be taken. This paper presents a method that is entirely ambulatory and noninvasive, using microelectromechanical systems (MEMS) accelerometers. The commonly used output of commercial accelerometer-based devices (known as "counts") cannot discriminate activity intensity for the activities of interest. This, in conjunction with variability in output from different systems and lack of commonality across manufacturers, limits the usefulness of commercial devices. This paper identifies anthropometric and kinematic sources of inter-athlete variability in accelerometer output, leading to an alternate energy expenditure estimator based mainly on step frequency modified by anthropometric measures. This energy expenditure estimator is more robust and not influenced by many sources of variability that affect the currently used estimator. In this system, low-power signal processing was implemented to extract both the energy estimator and other information of physiological and statistical interest.Griffith Sciences, Griffith School of EngineeringFull Tex